Introduction {#Sec1}
============

Radiotherapy for laryngopharyngeal cancer plays an important role for organ preservation \[[@CR1]--[@CR3]\]. However, it sometimes leads to functional disabilities including swallowing dysfunction \[[@CR2]--[@CR5]\]. One of the reasons for these disabilities is a deterioration of laryngeal sensation. Laryngeal sensation is an important factor in swallowing \[[@CR6]--[@CR9]\], but quantitative evaluation of laryngeal sensation has been difficult. Aviv et al. described the use of an air-puff stimulator for quantitative evaluation of laryngeal sensation \[[@CR7], [@CR10]\], but such testing has been limited because of the special equipment required. In the present study, a novel method to measure laryngeal sensation using a flexible laryngoscope and probes previously developed by Yaguchi et al. was used \[[@CR11], [@CR12]\]. Yaguchi et al. evaluated and compared laryngeal sensation in young adults and elderly individuals using this method. In the present study, the same method was used to evaluate changes in laryngeal sensation before and after radiotherapy for laryngeal and hypopharyngeal cancer.

Materials and methods {#Sec2}
=====================

This study was approved by the ethics committee and institutional review board of our hospital (No. 534, 534-2). All patients provided their written informed consent.

The study involved 12 patients with laryngeal (*n* = 8) or hypopharyngeal cancer (*n* = 4) who did not undergo surgery for the primary lesion, and underwent either radiotherapy alone or chemoradiotherapy. The patients' mean age was 66.2 years (range 53--78 years). Four patients underwent radiotherapy alone, and eight underwent chemoradiotherapy. All patients achieved a complete response of the primary lesion. In two patients, neck dissection on the side of the lesion was performed within 1 month after completing radiotherapy for residual cervical lymph nodes. Table [1](#Tab1){ref-type="table"} shows the patients' characteristics.Table 1Patients' characteristicsNo.AgeSexTumour siteTMNRadiotherapy dose (Gy)ChemotherapyOperation173MHypopharynxT1N0M070None278MLarynxT3N2cM066None365MHypopharynxT2N0M060Concomitant474MLarynxT2N2bM070ConcomitantND563MLarynxT1bN0M060Concomitant670MLarynxT1aN0M070None758MHypopharynxT1N0M066Concomitant869MHypopharynxT4bN2cM060Concomitant959FLarynxT1aN0M070None1073MLarynxT2N0M070Concomitant1153MLarynxT1N2bM066ConcomitantND1259MLarynxT2N0M060Concomitant*ND* neck dissection

The test procedure was as follows. A novel flexible laryngoscope (ENF-Y0005), with a maximum diameter of 3.3 mm and a 1.2-mm probe port was co-developed with Olympus (Tokyo, Japan) in previous research \[[@CR11], [@CR12]\]. When compared with a conventional flexible laryngoscope with a forceps port, this flexible laryngoscope is narrower, has a curvature angle of 130°, and has excellent manoeuvrability (Fig. [1](#Fig1){ref-type="fig"}). The probes, also co-developed with Olympus, have a nylon filament attached to a wire tip and are protected by a sheath to prevent entanglement with the flexible laryngoscope. Four types of probes with nylon filament diameters of 0.06, 0.13, 0.20, and 0.30 mm were used (Fig. [1](#Fig1){ref-type="fig"}). These were prepared based on Semmes--Weinstein monofilaments, which are used to test sensation, for example, in diabetic peripheral neuropathy \[[@CR12]\]. At the time of the study, the flexible laryngoscope and probes had not yet become commercially available, and they were provided by Olympus.Fig. 1Flexible laryngoscopes and probes. The *upper left photo* shows all of the flexible laryngoscopes. The *lower left photo* compares the tips of the laryngoscopes. The *top* is a conventional flexible laryngoscope, and the *bottom* is the novel, thinner, and flexible laryngoscope. The *right photo* is a magnified view of the probe tips. The nylon filament diameters are **a** 0.06, **b** 0.13, **c** 0.2, and **d** 0.3 mm

To insert the flexible laryngoscope without using intranasal anaesthesia, 1:2,000 epinephrine was gently applied to widen the nasal cavity. The flexible laryngoscope was inserted to the oropharynx, and the probes were placed in contact with the tip of the epiglottis and the arytenoid region mucosa (at a non-tumour site in cases of hypopharyngeal cancer). Sufficient contact was made so that there was a slight bending of the probe (Fig. [2](#Fig2){ref-type="fig"}). The flexible laryngoscope and probes were manipulated, whenever possible, by the same person. Patients were asked to ring a buzzer or tap their hand when they felt the probe. For objective evaluation, the laryngeal adductor reflex was observed. Agreement between the subjective and objective findings was considered "positive." Testing started with the thinnest probe, and the sensation level was based on the probe giving two of three positive responses.Fig. 2Laryngoscopic findings during measurement. The nylon filament extending out from the sheath tip is in contact with the epiglottis and the arytenoid region

Testing was performed four times; before radiotherapy, 1, 3 months, and 1 year after completing radiotherapy. Testing was stopped when the patient had severe pain or a strong gag reflex.

The Wilcoxon-signed rank test with Bonferroni correction was used to confirm significant differences between each testing time. A correlation between the sensation levels of the epiglottis and the arytenoid region was analysed using the Spearman's rank correlation. Comparison of sensation levels between mild mucositis and severe mucositis was analysed using the repeated measures analysis of variance test.

The grade of radiation mucositis was classified based on the National Cancer Institute's Common Terminology Criteria for Adverse Events v.3 (Table [2](#Tab2){ref-type="table"}).Table 2Radiation mucositis classification based on the National Cancer Institute's Common Terminology Criteria for Adverse Events v.3Grade 1Erythema of the mucosaGrade 2Patchy ulcerations or pseudomembranesGrade 3Confluent ulcerations or pseudomembranes; bleeding with minor traumaGrade 4Tissue necrosis; significant spontaneous bleeding; life-threatening consequencesGrade 5Death

Results {#Sec3}
=======

Laryngeal paralysis did not occur before or after treatment in any patient, and arytenoid adduction during phonation was preserved. In patients 8 and 9, sensation testing 1 year after radiotherapy was cancelled because of lung metastasis and personal reasons, respectively.

Figure [3](#Fig3){ref-type="fig"} shows the results of laryngeal sensation testing and the grade of radiation mucositis. Mucositis was mild in seven patients (grade 1 in 1 patient, grade 2 in 6 patients) and severe in five patients (grade 3 in 5 patients). All patients showed sensory deterioration of the epiglottis and/or the arytenoids until 3 months after radiotherapy. One year after radiotherapy, 60% of patients showed the same sensation levels in the epiglottis as before radiotherapy, or better sensation levels than at 1 or 3 months after radiotherapy. With respect to arytenoids sensation, 90% of patients showed the same sensation levels as before radiotherapy or better sensation levels than at 3 months after radiotherapy.Fig. 3The sensation levels of the epiglottis and arytenoid; before, 1, 3 months, and 1 year after radiotherapy in each patient. *Closed symbols* (*filled circle*, *filled triangle*, *filled square*, *filled diamond*, *filled inverted triangle*) are the severe mucositis group; other symbols are the mild mucositis group

With respect to sensation of the epiglottis, the Wilcoxon-signed rank test with Bonferroni correction showed a significant deterioration (*P* \< 0.017) in sensation 1 and 3 months after radiotherapy compared with before radiotherapy. However, there was no significant difference in sensation 1 year after radiotherapy when compared with before radiotherapy (*P* = 0.04). With respect to arytenoids sensation, the Wilcoxon-signed rank test with Bonferroni correction showed a significant deterioration (*P* \< 0.017) in sensation 1 and 3 month after radiotherapy when compared with before radiotherapy, but at 1 year, the difference was not significant when compared with before radiotherapy (*P* = 0.12). There was a significant correlation (*P* \< 0.0001) between the sensation levels of the epiglottis and the arytenoid region on the Spearman rank correlation.

Figure [3](#Fig3){ref-type="fig"} also compares the sensation levels between mild mucositis and severe mucositis; there were no significant differences on the repeated measures analysis of variance test for both the epiglottis (*P* = 0.09) and the arytenoid region (*P* = 0.58).

Discussion {#Sec4}
==========

Radiotherapy of the laryngopharynx sometimes leads to functional disabilities including swallowing dysfunction \[[@CR2]--[@CR5]\]. The reasons for these disabilities are mucosal and muscular inflammation, fibrosis, reduced saliva secretion and deterioration of laryngeal sensation \[[@CR4]\]. Laryngeal sensation is an important factor in swallowing \[[@CR11]\], and we decided to evaluate laryngeal sensation. Procedures for testing laryngeal sensation by laryngoscope include fiberoptic endoscopic evaluation of swallowing with sensory testing (FEESST) with an air-puff stimulator, as described by Aviv et al. \[[@CR10]\], direct mucosal contact with a flexible laryngoscope, and the use of probes, as discussed in the present report. FEESST is a minimally invasive procedure to quantify sensation by air pulses stimulating the laryngeal mucosa at a constant pressure and time \[[@CR13]--[@CR16]\], but the need for a special air-puff stimulator has limited its use. Direct contact with a flexible laryngoscope is simple, but it is not very quantitative, with large inter-operator variability. Our method using probes, originally described by Yaguchi et al. \[[@CR12]\], permits semiquantitative evaluation, is minimally invasive, and is convenient for use in clinical settings; it allowed us to evaluate changes in laryngeal sensation before and after radiotherapy.

First, the test method used in the present study and its development are described. The novel narrow flexible laryngoscope with probe port was considered more appropriate for sensation testing because it was less irritating and unlikely to touch other sites during testing. In selecting an appropriate diameter of nylon filament to use with this method, Yaguchi et al. \[[@CR12]\] considered Semmes--Weinstein monofilaments, which are used to measure tactile sensation by pressing nylon fibres against the skin. However, the thinnest commercially available nylon filament (diameter, 0.13 mm), in a kit from Arkray Inc. (Kyoto, Japan), is adequately perceived by the tongue. Therefore, Yaguchi et al. \[[@CR12]\] decided to develop a thinner nylon filament with half the diameter (0.06 mm), and selected four sizes of nylon filaments for testing: 0.06, 0.13, 0.2, and 0.3 mm. We considered these sizes optimal for sensation testing, and the same size nylon filaments were used in the present study.

Our selection of measurement sites (the epiglottic tip and the arytenoid) was also based on the previous research \[[@CR12]\]. These areas are innervated mainly by the superior laryngeal nerve, have a dense distribution of sensory fibres, and are relatively accessible to testing.

In determining the sensation level, Aviv et al. \[[@CR16]\] and Yaguchi et al. \[[@CR12]\] used subjective and objective findings, and a "positive" sensory response was based on the agreement between findings. Both authors reported a high correlation between findings. Therefore, in the present study, as in previous research, a "positive" response was based on the agreement between subjective and objective findings.

When evaluating laryngeal sensation using a flexible laryngoscope, Yaguchi et al. \[[@CR12]\] limited the number of contacts to avoid patient discomfort, and estimated the sensation level based on two of three positive responses. Accordingly, in the present study, sensation level was based on two of three positive responses. Although increasing the number of contacts may improve repeatability and precision, we were concerned that increasing the number of contacts might be painful and uncomfortable for patients and may increase the study dropout rate.

Next, the measurement results are described. In this study, in both the epiglottis and the arytenoid, laryngeal sensation deteriorated significantly 1 and 3 month after radiotherapy compared with before radiotherapy. Parise et al. \[[@CR14]\] evaluated laryngeal sensation in patients with dysphagia by FEESST, and they reported a direct association between radiotherapy of the head and neck and severe laryngeal sensation deficits. The present study also clearly demonstrates the deterioration of laryngeal sensation with radiotherapy. On the other hand, 1 year after radiotherapy, there was no significant difference compared with before radiotherapy for both the epiglottis and the arytenoid. As mentioned in our results, most patients showed the same sensation levels as before radiotherapy, or better sensation levels than 3 months after radiotherapy. Laryngeal sensation tended to recover 1 year after radiotherapy. However, we suggest the testing should be repeated 2 or 3 years after radiotherapy. According to Dietz et al. \[[@CR2]\], 16% of patients who underwent chemoradiatiotherapy for larynx/hypopharynx carcinoma still showed dysphagia 3 years after chemoradiotherapy.

In the present study, a significant correlation was observed between the sensation levels of the epiglottis and the arytenoid region. The probes could be inserted into the forceps port of a conventional flexible laryngoscope. Therefore, in cases where tests are conducted using a conventional laryngoscope with a rather long diameter with a forceps port, or where measurement in the arytenoid region is difficult due to severe pain, it may be possible to determine deterioration of sensation in the arytenoid region to some degree by measuring the sensation in the epiglottis.

The reasons for deterioration of laryngeal sensation after radiotherapy need to be considered. Bodin et al. \[[@CR17]\] reported that a dose of 64 Gy in the head and neck field can damage sensory nerves. Another study reported peripheral neuropathy in 75% of patients receiving radiotherapy doses of 63 Gy \[[@CR18]\]. Neuropathologic features in peripheral neuropathy include necrosis and hyalinization of the media of small arteries, fibrous replacement of nerve fibres, demyelination, and fibrosis of the nerve sheath \[[@CR19]\]. In the present study, 3 of 12 patients received 60 Gy, and the other 9 patients had doses of 66--70 Gy; thus, peripheral neuropathy was highly likely.

The loss of sensory receptors was also considered because, in a study on taste dysfunction in patients receiving radiotherapy to the oropharynx, pathologic analyses showed diminished taste buds \[[@CR20]\]. In the same manner, radiotherapy of the laryngopharynx probably causes loss of sensory receptors.

In the present study, there was no significant difference in sensory deterioration and sensory recovery between the severe radiation mucositis group and the mild radiation mucositis group. However, based on the underlying mechanism, a correlation between grade of radiation mucositis and deterioration of laryngeal sensation is possible. This issue must be further investigated by accumulating more cases.

Finally, there have been reports of peripheral paresthesia caused by anticancer agents \[[@CR21]--[@CR23]\]. In the present study, we did not find a significant difference in deterioration and recovery of sensation with the combination of chemotherapy and radiotherapy, but this issue must also be further investigated by accumulating more cases.

Conclusion {#Sec5}
==========

A novel procedure using a flexible laryngoscope and probes allowed convenient evaluation of changes in laryngeal sensation in patients before and after radiotherapy. In both the epiglottis and the arytenoid, laryngeal sensation deteriorated significantly after radiotherapy. One year after radiotherapy, laryngeal sensation recovered in most cases.
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